You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
AstraZeneca
Baxter
Harvard Business School
Express Scripts

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LENVIMA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lenvima

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02430714 Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) Recruiting Eisai Co., Ltd. N/A 2015-05-01 This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.
NCT02579616 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Active, not recruiting Eisai Co., Ltd. Phase 2 2015-10-01 This is a multicenter, single arm, open-label study in participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent). This study contains 3 phases: a Pre-treatment phase that will last within 21 days; a Treatment phase that will consist of study treatment cycles and tumor assessment conducted every 6-8 weeks; and a Follow-up phase that will begin immediately after the Off-Treatment Visit and will continue as long as the participant is alive, unless the participant withdraws consent, or until the End of Study.
NCT02592356 Tyrosine Kinase Inhibitors (TKI) and Body Composition Recruiting M.D. Anderson Cancer Center N/A 2015-11-01 The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lenvima

Condition Name

Condition Name for Lenvima
Intervention Trials
Advanced Cancer 3
Liver Transplant; Complications 2
Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lenvima
Intervention Trials
Carcinoma 6
Thyroid Neoplasms 5
Thyroid Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lenvima

Trials by Country

Trials by Country for Lenvima
Location Trials
United States 29
Japan 8
United Kingdom 7
France 6
Germany 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lenvima
Location Trials
Texas 4
Massachusetts 4
California 3
Pennsylvania 2
Oregon 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lenvima

Clinical Trial Phase

Clinical Trial Phase for Lenvima
Clinical Trial Phase Trials
Phase 3 1
Phase 2 15
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lenvima
Clinical Trial Phase Trials
Not yet recruiting 14
Recruiting 8
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lenvima

Sponsor Name

Sponsor Name for Lenvima
Sponsor Trials
Eisai Inc. 8
Merck Sharp & Dohme Corp. 7
Eisai Co., Ltd. 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lenvima
Sponsor Trials
Other 20
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.